# OnCo record propel (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/propel/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "propel", "NCT03732820" ;
  schema:name "PROpel"@en ;
  schema:description "Showed PARP inhibitor plus abiraterone delays progression in first-line mCRPC, with the largest benefit in BRCA-mutant men."@en ;
  schema:url <https://onco.cc/trials/propel/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03732820>, <https://www.nice.org.uk/guidance/ta951> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-10-31" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/prostate-hrr-eligibility/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/talapro-2/>, <https://onco.cc/trials/magnitude/>, <https://onco.cc/trials/profound/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-propel-lancet-oncol-2023/> .